XML 63 R42.htm IDEA: XBRL DOCUMENT
v3.20.4

Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019
Revenue |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 47.00% |
Revenue | The Big Ten Conference |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 30.00% |
Revenue | Centura Healthcare |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 17.00% |
Revenue | Medicare |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 17.00% | 36.00%
Revenue | Covance Central Laboratory Services |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage |  | 21.00%
Accounts Receivable |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 76.00% | 83.00%
Accounts Receivable | The Big Ten Conference |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 35.00% |
Accounts Receivable | Centura Healthcare |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 24.00% |
Accounts Receivable | Medicare |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 6.00% | 18.00%
Accounts Receivable | Covance Central Laboratory Services |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 2.00% | 43.00%
Accounts Receivable | Janssen Research and Development, LLC |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 5.00% | 12.00%
Accounts Receivable | Pfizer, Inc |  |
Concentration Risk [Line Items] |  |
Concentration risk, percentage | 4.00% | 10.00%

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bdsx_CenturaHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bdsx_MedicareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bdsx_CovanceCentralLaboratoryServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bdsx_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |